Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways

The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology...

Descripción completa

Detalles Bibliográficos
Autor principal: Hoverman, J. Russell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404003/
https://www.ncbi.nlm.nih.gov/pubmed/32524722
http://dx.doi.org/10.1002/cam4.3193
_version_ 1783567055716352000
author Hoverman, J. Russell
author_facet Hoverman, J. Russell
author_sort Hoverman, J. Russell
collection PubMed
description The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value‐based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value.
format Online
Article
Text
id pubmed-7404003
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74040032020-08-06 Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways Hoverman, J. Russell Cancer Med Clinical Cancer Research The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value‐based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value. John Wiley and Sons Inc. 2020-06-10 /pmc/articles/PMC7404003/ /pubmed/32524722 http://dx.doi.org/10.1002/cam4.3193 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Hoverman, J. Russell
Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
title Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
title_full Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
title_fullStr Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
title_full_unstemmed Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
title_short Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
title_sort rethinking clinical oncology drug research in an era of value‐based cancer care: a role for chemotherapy pathways
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404003/
https://www.ncbi.nlm.nih.gov/pubmed/32524722
http://dx.doi.org/10.1002/cam4.3193
work_keys_str_mv AT hovermanjrussell rethinkingclinicaloncologydrugresearchinaneraofvaluebasedcancercarearoleforchemotherapypathways

Ejemplares similares